Harmony Biosciences Holdings Inc

For the period ended Mar 31, 2024. Filed Apr 30, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed Apr 30, 2024

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


· March 31, · December 31,
· 2024 · 2023
ASSETS · ·
CURRENT ASSETS: · ·
Cash and cash equivalents	$332,981	$311,660
Investments, short-term	39,369	41,800
Trade receivables, net	79,719	74,140
Inventory, net	5,857	5,363
Prepaid expenses	12,894	12,570
Other current assets	8,683	5,537
Total current assets	479,503	451,070
NONCURRENT ASSETS:
Property and equipment, net	213	371
Restricted cash	270	270
Investments, long-term	81,244	72,169
Intangible assets, net	131,147	137,108
Deferred tax asset	147,639	144,162
Other noncurrent assets	6,969	6,298
Total noncurrent assets	367,482	360,378
TOTAL ASSETS	$846,985	$811,448
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables	$15,144	$17,730
Accrued compensation	7,317	23,747
Accrued expenses	91,699	99,494
Current portion of long-term debt	15,000	15,000
Other current liabilities	25,093	7,810
Total current liabilities	154,253	163,781
NONCURRENT LIABILITIES:
Long-term debt, net	174,996	178,566
Other noncurrent liabilities	2,342	2,109
Total noncurrent liabilities	177,338	180,675
TOTAL LIABILITIES	331,591	344,456
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS’ EQUITY:
Common stock—$0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid in capital	620,507	610,266
Accumulated other comprehensive (loss) income	(171)	2
Accumulated deficit	(104,943)	(143,277)
TOTAL STOCKHOLDERS’ EQUITY	515,394	466,992
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$846,985	$811,448

UNAUDITED CONDENSED CONSOLIDATED

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.